<?xml version="1.0" encoding="UTF-8"?>
<ref id="B19-molecules-26-02880">
 <label>19.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Malakouti-Nejad</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Bardania</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>Aliakbari</surname>
    <given-names>F.</given-names>
   </name>
   <name>
    <surname>Baradaran-Rafii</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Elahi</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Monti</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Morshedi</surname>
    <given-names>D.</given-names>
   </name>
  </person-group>
  <article-title>Formulation of nanoliposome-encapsulated bevacizumab (Avastin): Statistical optimization for enhanced drug encapsulation and properties evaluation</article-title>
  <source>Int. J. Pharm.</source>
  <year>2020</year>
  <volume>590</volume>
  <fpage>119895</fpage>
  <pub-id pub-id-type="doi">10.1016/j.ijpharm.2020.119895</pub-id>
  <?supplied-pmid 32956821?>
  <pub-id pub-id-type="pmid">32956821</pub-id>
 </element-citation>
</ref>
